SCHEMBL2406832

SCHEMBL2406832

CC(=O)NCC1CN(c2cccc(F)c2N2CCOCC2)C(=O)O1

nearest known ligand 0.67

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
MAOB P27338 6/20 0.67
MAOA P21397 5/20 0.67
PTGS1 P23219 2/20 0.67
SDHA P31040 2/20 0.67
LMNA P02545 1/20 0.67
CALML3 P27482 1/20 0.67
F10 P00742 4/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2591003 1.00 MAOB (0.67) MAOBMAOAPTGS1SDHALMNA
SCHEMBL2406825 1.00 MAOB (0.67) MAOBMAOAPTGS1SDHALMNA
SCHEMBL6854026 0.89 MAOA (0.53) MAOBMAOAPTGS1SDHALMNA
SCHEMBL28998570 0.85 MAOB (0.68) MAOBMAOAPTGS1SDHALMNA
SCHEMBL27801851 0.85 MAOB (0.68) MAOBMAOAPTGS1SDHALMNA
SCHEMBL2046431 0.84 MAOB (0.46) MAOBMAOAPTGS1SDHALMNA
SCHEMBL7030086 0.84 MAOB (0.61) MAOBMAOAPTGS1SDHALMNA
SCHEMBL3181066 0.84 MAOA (0.60) MAOBMAOAPTGS1SDHALMNA
SCHEMBL6097931 0.84 MAOB (0.48) MAOBMAOAPTGS1SDHALMNA
SCHEMBL3519815 0.84 MAOB (0.48) MAOBMAOAPTGS1SDHALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030216572-A1 PROCESS TO PRODUCE OXAZOLIDINONES PHARMACIA & UPJOHN COMPANY 2003-11-20 US claimed
US-20030130509-A1 PROCESS TO PRODUCE 3-CARBON AMINO ALCOHOL SALTS PHARMACIA & UPJOHN COMPANY 2003-07-10 US claimed
US-20020032348-A1 Process to produce oxazolidinones PEARLMAN BRUCE ALLEN (US) 2002-03-14 US claimed
CN-115236236-A Linezolid and separation and analysis method of enantiomers in preparation thereof 上海市食品药品检验研究院 2022-10-25 CN disclosed
CN-113995726-A Linezolid II crystal form tablet and preparation method thereof 深圳万乐药业有限公司 2022-02-01 CN disclosed
CN-113045509-B Industrial production method of linezolid 上海翰森生物医药科技有限公司 2021-10-22 CN disclosed
CN-113045509-A Industrial production method of linezolid 上海翰森生物医药科技有限公司 2021-06-29 CN disclosed
US-RE47606-E1 Process for the preparation of linezolid OPTIMUS DRUGS PRIVATE LIMITED (IN) 2019-09-17 US disclosed
EP-2899185-B1 Processes for preparing linezolid UNIV INDIANA RES & TECH CORP (US) 2018-01-31 EP disclosed
EP-3250568-A1 AN IMPROVED PROCESS FOR THE PREPARATION OF LINEZOLID Optimus Drugs Pvt Ltd (IN) 2017-12-06 EP disclosed
WO-2017182853-A1 AN IMPROVED PROCESS FOR THE PREPARATION OF LINEZOLID OPTIMUS DRUGS PVT LTD (IN) 2017-10-26 WO disclosed
WO-2002085849-A2 PROCESS TO PREPARE OXAZOLIDINONES PHARMACIA & UPJOHN COMPANY (US) 2002-10-31 WO disclosed
US-20020095054-A1 Process to produce oxazolidinones PHARMACIA & UPJOHN COMPANY 2002-07-18 US disclosed
US-6410788-B1 BACTERICIDES; REACTING IMINE, CARBAMATE, ESTER, AMIDE AND EPOXIDE DERIVATIVES PHARMACIA & UPJOHN COMPANY 2002-06-25 US disclosed
US-6362334-B1 OXAZOLIDINONE PHTHALAMIDE PHARMACIA & UPJOHN COMPANY 2002-03-26 US disclosed
US-20020032348-A1 Process to produce oxazolidinones PEARLMAN BRUCE ALLEN (US) 2002-03-14 US disclosed
US-6239152-B1 Oxazolidinone combinatorial libraries, compositions and methods of preparation PHARMACIA & UPJOHN COMPANY 2001-05-29 US disclosed
EP-1049682-A1 OXAZOLIDINONE COMBINATORIAL LIBRARIES, COMPOSITIONS AND METHODS OF PREPARATION Versicor, Inc. (US) 2000-11-08 EP disclosed
US-6107519-A Process to produce oxazolidinones PHARMACIA & UPJOHN COMPANY (US) 2000-08-22 US disclosed
WO-1999037630-A1 OXAZOLIDINONE COMBINATORIAL LIBRARIES, COMPOSITIONS AND METHODS OF PREPARATION VERSICOR, INC. (US) 1999-07-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030130509-A1 PROCESS TO PRODUCE 3-CARBON AMINO ALCOHOL SALTS ADH1A, ADH5, ADH1C MAOB 652/4885MAOA 413/4885PTGS1 3186/4885
US-20020095054-A1 Process to produce oxazolidinones ADH1A, ADH5, ADH1C MAOB 189/4885MAOA 156/4885PTGS1 2552/4885
US-20030216572-A1 PROCESS TO PRODUCE OXAZOLIDINONES ADH1A, ADH5, ADH1C MAOB 189/4885MAOA 156/4885PTGS1 2552/4885
US-20020032348-A1 Process to produce oxazolidinones ADH1A, ADH5, ADH1C MAOB 189/4885MAOA 156/4885PTGS1 2552/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.